Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334879 · ClinicalTrials.gov registry record · Phase 1
High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
A Phase 1 study of Radiation Retinopathy, sponsored by The New York Eye Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01334879: Completed Phase 1 study of Radiation Retinopathy, sponsored by The New York Eye Cancer Center.
NCT01334879 is a Phase 1 study of Radiation Retinopathy that has completed, run by The New York Eye Cancer Center. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01334879, a Phase 1 study of Radiation Retinopathy, has completed, sponsored by The New York Eye Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.
Primary Outcome
All subjects will be assessed at baseline, at 7 days after first injection, and monthly for adverse events. The primary outcome measures for safety and tolerability are: 1. incidence and severity of ocular adverse events, as identified by eye examination (including best corrected visual acuity testing) and 2. Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs
Conditions Studied
Interventions
- DRUG ranibizumab 2.0 mg
Study Locations (1)
New York
- The New York Eye Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT01334879 record still lists
NCT01334879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Radiation Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab 2.0 mg is the first listed.
NCT01334879 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01334879 about?
NCT01334879 is a clinical study titled "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy". This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.
What is the current status of trial NCT01334879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-05. Estimated completion is 2012-11.
What conditions does trial NCT01334879 study?
This clinical trial studies the following conditions: Radiation Retinopathy.
What interventions are being tested in trial NCT01334879?
The interventions under investigation include: ranibizumab 2.0 mg (DRUG).
Who is sponsoring clinical trial NCT01334879?
This trial is sponsored by The New York Eye Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01334879 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01334879's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia